Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor-Reference-Cited by-同舟云学术

Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor

Published:2013-01-25 Issue:3 Volume:229 Page:422-429
ISSN:0022-3417
Container-title:The Journal of Pathology
language:en
Short-container-title:J. Pathol.

Author:

Barber Louise J¹,Sandhu Shahneen²,Chen Lina¹,Campbell James¹,Kozarewa Iwanka¹,Fenwick Kerry¹,Assiotis Ioannis¹,Rodrigues Daniel Nava¹,Reis-Filho Jorge S¹,Moreno Victor²,Mateo Joaquin²,Molife L Rhoda²,De Bono Johann²,Kaye Stan²,Lord Christopher J¹,Ashworth Alan¹

Affiliation:

1. Breakthrough Breast Cancer Research Centre; Institute of Cancer Research; London UK

2. Royal Marsden NHS Foundation Trust and Institute of Cancer Research; Sutton Surrey UK

Publisher

Wiley

Subject

Pathology and Forensic Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/path.4140/fullpdf

Reference18 articles.

1. BRCA1 and BRCA2: different roles in a common pathway of genome protection;Roy;Nat Rev Cancer,2012

2. Germline mutations in RAD51D confer susceptibility to ovarian cancer;Loveday;Nat Genet,2011